發(fā)布時(shí)間：2018-06-07 16:03

  本文選題：碳酸鑭 + 醋酸鈣�。� 參考：《中國(guó)臨床藥理學(xué)雜志》2017年16期

【摘要】：目的觀察碳酸鑭聯(lián)合醋酸鈣治療維持性血液透析患者高磷血癥的臨床療效。方法將70例維持性血液透析高磷血癥患者隨機(jī)分為試驗(yàn)組35例和對(duì)照組35例。對(duì)照組給予醋酸鈣片,起始劑量為醋酸鈣片667 mg,每日3次,口服;試驗(yàn)組在對(duì)照組的基礎(chǔ)上給予碳酸鑭咀嚼片250 mg,每日3次,口服。2組均治療12周。評(píng)價(jià)2組患者的臨床療效及血磷、血鈣、甲狀旁腺素水平(iPTH),并觀察2組的藥物不良反應(yīng)發(fā)生情況。結(jié)果治療后,試驗(yàn)組降磷總有效率91.43%(32/35例),對(duì)照組為71.43%(25/35例),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療后,試驗(yàn)組血磷、血鈣、iPTH分別為(1.73±0.16)mmol·L~(-1),(2.25±0.15)mmol·L~(-1),(189.60±68.49)pg·mL~(-1),對(duì)照組分別為(1.88±0.29)mmol·L~(-1),(2.45±0.19)mmol·L~(-1),(217.83±64.00)pg·mL~(-1),差異均有統(tǒng)計(jì)學(xué)意義(均P0.05)。試驗(yàn)組出現(xiàn)惡心嘔吐2例,藥物不良反應(yīng)率為5.71%(2/35例);對(duì)照組出現(xiàn)腹痛1例,藥物不良反應(yīng)率為2.86%(1/35例);2組藥物不良反應(yīng)發(fā)生率差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論碳酸鑭聯(lián)合醋酸鈣可有效治療維持性血液透析患者高磷血癥,且安全性較好。
[Abstract]:Objective to observe the clinical effect of lanthanum carbonate combined with calcium acetate on hyperphosphatemia in maintenance hemodialysis patients. Methods 70 patients with maintenance hemodialysis hyperphosphatemia were randomly divided into trial group (n = 35) and control group (n = 35). The control group was given calcium acetate tablets at the initial dose of 667 mg, 3 times a day, and the experimental group was given 250 mg of lanthanum carbonate chewable tablets, 3 times a day, on the basis of the control group, for 12 weeks. Objective: to evaluate the clinical efficacy, serum phosphorus, serum calcium and parathyroid hormone levels of iPTHG in two groups, and to observe the occurrence of adverse drug reactions in the two groups. Results after treatment, the total effective rate of reducing phosphorus was 91.43 / 32 / 35 in the experimental group and 71.43 / 25 / 35 in the control group. The difference was statistically significant (P 0.05). After treatment, the levels of serum phosphorus and calcium in the experimental group were 1.73 鹵0.16)mmol / L ~ (-1) respectively, were 2.25 鹵0.15)mmol / L ~ (-1) and 189.60 鹵68.49)pg / mL ~ (-1), respectively, while those in the control group were 2.45 鹵0.19)mmol / L ~ (-1) and 217.83 鹵64.00)pg / mL ~ (-1), respectively (P < 0.05). There were 2 cases of nausea and vomiting in the trial group, the adverse drug reaction rate was 5.71% / 35 cases, in the control group, there was abdominal pain in 1 case, and the adverse drug reaction rate was 2.86% in 35 cases. There was no significant difference in the incidence of adverse drug reactions between the two groups (P 0.05). Conclusion Lanthanum carbonate combined with calcium acetate can effectively treat hyperphosphatemia in maintenance hemodialysis patients, and it is safe.
【作者單位】： 金華市中心醫(yī)院腎內(nèi)科;
【基金】：浙江省衛(wèi)生廳科研基金資助項(xiàng)目(2012KYB227)
【分類號(hào)】：R692.5

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 劉曉琴;李英;施月仙;;慢性腎臟病透析并高磷血癥病人的飲食治療現(xiàn)狀[J];護(hù)理研究;2012年07期

2 呂泰虎;白霞;宋立萍;田玉梅;王海燕;;非藥物治療對(duì)血液透析患者高磷血癥的療效觀察[J];中國(guó)衛(wèi)生產(chǎn)業(yè);2013年09期

3 鄭良宏;高波;;不同磷結(jié)合劑治療維持性血液透析患者高磷血癥的療效觀察[J];實(shí)用臨床醫(yī)藥雜志;2014年01期

4 徐耀文;汪關(guān)煜;錢瑩;朱萍;吳霞s，

本文編號(hào)：1991769